Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Overweight × Bupropion × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1 Breast 1

Conditions

Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 2 Tobacco Use Disorder 2 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Pancreatic Neoplasms 2 Oropharyngeal Neoplasms 2 Nasopharyngeal Neoplasms 2 Mouth Neoplasms 2 Lung Neoplasms 2 Liver Neoplasms 2 Leukemia, Myeloid, Acute 2 Leukemia 2 Laryngeal Neoplasms 2 Kidney Neoplasms 2 Hypopharyngeal Neoplasms 2 Head and Neck Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Overweight 1 Ovarian Neoplasms 1 Obesity 1 Melanoma 1

Interventions

sultamicillin 1 licogliflozin 1 drospirenone and ethinyl estradiol combination 1 drospirenone 1 bupropion hydrochloride, naltrexone hydrochoride drug combination 1 Sugars 1 Naltrexone 1 Flutamide 1 Exenatide 1 Ethinyl Estradiol 1 Bupropion 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04499950 2025-03-06

A-NEW

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed

53 enrolled 14 charts

Breast Neoplasms, Obesity, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon ⚡